Elvira Meni Maria Gkrinia,Andrej Belančić,Ivana Stević et al.
Elvira Meni Maria Gkrinia et al.
Introduction: The emergence of high-cost therapies, particularly in oncology, rare diseases, and advanced therapy medicinal products, has increased the need for robust pharmacoeconomic evaluations to support healthcare de...
Universal school-based mental health promotion in Vietnam: a critical appraisal of a health-economic evaluation [0.03%]
越南普遍开展学校精神健康促进活动的卫生经济学评价述评
Afschin Gandjour
Afschin Gandjour
A recent cost-utility analysis modeled the long-term cost-effectiveness of a universal, teacher-delivered school mental health program for adolescents in Vietnam. This key paper evaluation discusses how modeling choices - particularly the t...
REFLECTIVE-TIAB: cost-effective prompt optimisation for large language model-based title and abstract screening in literature reviews [0.03%]
基于大型语言模型的文献回顾中的标题和摘要筛选的成本效益型提示优化(Reflective-TIAB)
Ákos Józwiak,Attila Imre,Judit Hagymásy et al.
Ákos Józwiak et al.
Background: Title and abstract screening is a labor-intensive stage of systematic reviews. Large language models (LLMs) can automate this process, but performance depends heavily on prompt design and model selection, whic...
Outcome measures for fear of movement in individuals with musculoskeletal disorders: a systematic review with meta- analysis [0.03%]
肌骨系统疾病患者运动恐惧症结局测量指标的系统评价及meta分析
Martina Tomassini,Ilaria Ruotolo,Alessandro Ugolini et al.
Martina Tomassini et al.
Introduction: Fear of movement is a significant psychological factor in musculoskeletal disorders, negatively impacting clinical outcome. Currently there are many assessment tools measuring the fear of movement. This syst...
Impact of clinical pharmacist-led antimicrobial stewardship on prescribing optimization and economic outcomes in a Chinese county hospital: a retrospective cohort study [0.03%]
临床药剂师领导的抗菌药物管理对中国县级医院处方优化和经济效益的影响：回顾性队列研究
Gao-Yi Yi,Hong-Mei Diao,Qiang Zhou et al.
Gao-Yi Yi et al.
Background: Clinical pharmacist-led antimicrobial stewardship (AMS) programs have proven effective in tertiary care, yet rigorous pharmacoeconomic evidence from primary care remains limited. This study evaluates the cost-...
Budget impact analysis of capivasertib as a second-line therapy for advanced breast cancer in the United States [0.03%]
卡培斯韦替布在美国作为晚期乳腺癌二线疗法的成本影响分析
Trang Nguyen,Shweta Mital
Trang Nguyen
Background: Capivasertib was the first AKT inhibitor approved by the US FDA as a second-line treatment for PIK3CA/AKT1/PTEN-altered, HR+/HER2- advanced breast cancer. However, capivasertib is costly. This study provides t...
Patient centered and technology enabled strategies to improve Tuberculosis treatment adherence [0.03%]
以患者为中心的技术支持策略改善肺结核治疗依从性
Malaisamy Muniyandi,Sahil Abdul Salam,Karikalan Nagarajan
Malaisamy Muniyandi
Introduction: Tuberculosis (TB) treatment adherence (how regular patients follow the prescribed medication) has a major role in TB control. In high burden countries such as India, poor adherence contributes to treatment f...
Differences in evidentiary requirements for oncology drug assessments across Health Technology assessment bodies in Germany, Spain, and France, the European Medicines Agency, and the EU Health Technology assessment Regulation [0.03%]
德国、西班牙和法国的卫生技术评估机构、欧洲药品管理局及欧盟卫生技术评估条例在肿瘤药物评估中的证据要求差异性分析
Amber Tiemens,Christophe Sauboin,Sharon Wolters et al.
Amber Tiemens et al.
Background: This study compares evidentiary requirements for oncology drugs across the European Medicines Agency (EMA), the EU Health Technology Assessment Regulation (HTAR), and national Health Technology Assessment (HTA...
Effectiveness and cost-effectiveness of pembrolizumab in persistent, recurrent, or metastatic cervical cancer with PD-L1 CPS 1-10: secondary analysis of KEYNOTE-826 using innovative KMSubtraction [0.03%]
帕博利珠单抗治疗PD-L1 CPS 1-10的持续、复发或转移性宫颈癌的疗效和成本效益：KEYNOTE-826研究的创新KMSubtraction法二级分析结果
Jin Zhou,Jiaqin Cai,Lirong Zhang et al.
Jin Zhou et al.
Background: To evaluate the effectiveness and cost-effectiveness of pembrolizumab combined with chemotherapy and anti-angiogenesis treatment for PD-L1 CPS 1-10 cervical cancer (CC) patients from the perspective of US heal...
Challenges of using AI-based synthetic data in Health economics and Outcomes Research [0.03%]
基于人工智能的合成数据在健康经济与结果研究中的挑战
Arindam Saha,Zongliang Yue,Surachat Ngorsuraches
Arindam Saha
Introduction: The growing demand for artificial intelligence (AI)-generated synthetic data (SD) in health economics and outcome research (HEOR) offers both opportunities and risks. As SD might be used in the near future t...